CLS-003

CLS-003 is an investigational drug candidate being developed by Comera Life Sciences for the treatment of Telomere Syndrome, a group of rare congenital disorders characterized by abnormally short telomeres. The program is currently in the discovery stage of development. Comera Life Sciences specializes in the formulation of biologics for subcutaneous administration using its proprietary SQore™ technology platform. This platform utilizes specific excipients to reduce the viscosity and improve the stability of high-concentration protein formulations, potentially enabling the conversion of intravenous (IV) therapies into subcutaneous (SQ) injections for easier self-administration. While CLS-003 is identified as a pipeline candidate for Telomere Syndrome, specific details regarding its active ingredient, molecular target, or mechanism of action have not been publicly disclosed.

Other names

Ionic Contra-viral TherapyICVT